Clinical trial

Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer

NCT02793219

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2016-12-01

PhasePHASE2

Study timeline

Study start (estimated)2016-12-01Date precision: month

Registry last updated2017-10-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

Sipuleucel-TBIOLOGICAL

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

The University of Texas Health Science Center, Houstonlead sponsor

Mapped research locations

HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02793219 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.